-
1
-
-
33847213152
-
A meta-analysis of the placebo rates of remission and response in clinical trials of active ulcerative colitis
-
Su C, Lewis JD, Goldberg B, et al. A meta-analysis of the placebo rates of remission and response in clinical trials of active ulcerative colitis. Gastroenterology. 2007;132:516-526.
-
(2007)
Gastroenterology
, vol.132
, pp. 516-526
-
-
Su, C.1
Lewis, J.D.2
Goldberg, B.3
-
2
-
-
84968747329
-
Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis
-
Timmer A,McDonald JW,Macdonald JK. Azathioprine and 6-mercaptopurine for maintenance of remission in ulcerative colitis. Cochrane Database Syst Rev. 2007;9:CD000478.
-
(2007)
Cochrane Database Syst Rev
, vol.9
-
-
Timmer, A.1
McDonald, J.W.2
Macdonald, J.K.3
-
3
-
-
28844473957
-
Infliximab for induction and maintenance therapy for ulcerative colitis
-
Rutgeerts P, Sandborn WJ, Feagan BG, et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005;353:2462-2476.
-
(2005)
N Engl J Med
, vol.353
, pp. 2462-2476
-
-
Rutgeerts, P.1
Sandborn, W.J.2
Feagan, B.G.3
-
4
-
-
41349088375
-
Risk factors for opportunistic infections in patients with inflammatory bowel disease
-
Toruner M, Loftus EV Jr, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008;134:929-936.
-
(2008)
Gastroenterology
, vol.134
, pp. 929-936
-
-
Toruner, M.1
Loftus Jr., E.V.2
Harmsen, W.S.3
-
5
-
-
44949242296
-
Immunosuppressant medications and mortality in inflammatory bowel disease
-
quiz 1436
-
Lewis JD, Gelfand JM, Troxel AB, et al. Immunosuppressant medications and mortality in inflammatory bowel disease. Am J Gastroenterol. 2008; 103:1428-1435; quiz 1436.
-
(2008)
Am J Gastroenterol
, vol.103
, pp. 1428-1435
-
-
Lewis, J.D.1
Gelfand, J.M.2
Troxel, A.B.3
-
6
-
-
33646147141
-
Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry
-
Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol. 2006;4:621-630.
-
(2006)
Clin Gastroenterol Hepatol
, vol.4
, pp. 621-630
-
-
Lichtenstein, G.R.1
Feagan, B.G.2
Cohen, R.D.3
-
7
-
-
0347991877
-
The safety profile of infliximab in patients with Crohn's disease: The Mayo clinic experience in 500 patients
-
Colombel JF, Loftus EV Jr, Tremaine WJ, et al. The safety profile of infliximab in patients with Crohn's disease: the Mayo clinic experience in 500 patients. Gastroenterology. 2004;126:19-31.
-
(2004)
Gastroenterology
, vol.126
, pp. 19-31
-
-
Colombel, J.F.1
Loftus Jr., E.V.2
Tremaine, W.J.3
-
8
-
-
77950988234
-
Infliximab azathioprine or combination therapy for Crohn's disease
-
Colombel JF, Sandborn WJ, Reinisch W, et al. Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 2010;362: 1383-1395.
-
(2010)
N Engl J Med
, vol.362
, pp. 1383-1395
-
-
Colombel, J.F.1
Sandborn, W.J.2
Reinisch, W.3
-
9
-
-
67949112671
-
Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: A meta-analysis
-
Siegel CA, Marden SM, Persing SM, et al. Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis. Clin Gastroenterol Hepatol. 2009;7:874-881.
-
(2009)
Clin Gastroenterol Hepatol
, vol.7
, pp. 874-881
-
-
Siegel, C.A.1
Marden, S.M.2
Persing, S.M.3
-
10
-
-
22644446331
-
Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine
-
Kandiel A, Fraser AG, Korelitz BI, et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut. 2005;54:1121-1125.
-
(2005)
Gut
, vol.54
, pp. 1121-1125
-
-
Kandiel, A.1
Fraser, A.G.2
Korelitz, B.I.3
-
11
-
-
84855351626
-
The incidence of hepatosplenic T-cell lymphoma in a large managed care organization, with reference to anti-tumor necrosis factor therapy, Northern California, 2000-2006
-
Herrinton LJ, Liu L, Abramson O, et al. The incidence of hepatosplenic T-cell lymphoma in a large managed care organization, with reference to anti-tumor necrosis factor therapy, Northern California, 2000-2006. Pharmacoepidemiol Drug Saf. 2012;21:49-52.
-
(2012)
Pharmacoepidemiol Drug Saf
, vol.21
, pp. 49-52
-
-
Herrinton, L.J.1
Liu, L.2
Abramson, O.3
-
12
-
-
84872024555
-
T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-alpha) inhibitors: Results of the REFURBISH study
-
Deepak P, Sifuentes H, Sherid M, et al. T-cell non-Hodgkin's lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-alpha) inhibitors: results of the REFURBISH study. Am J Gastroenterol. 2013; 108:99-105.
-
(2013)
Am J Gastroenterol
, vol.108
, pp. 99-105
-
-
Deepak, P.1
Sifuentes, H.2
Sherid, M.3
-
13
-
-
33748126607
-
Do patient preferences influence decisions on treatment for patients with steroid-refractory ulcerative colitis?
-
Arseneau KO, Sultan S, Provenzale DT, et al. Do patient preferences influence decisions on treatment for patients with steroid-refractory ulcerative colitis? Clin Gastroenterol Hepatol. 2006;4:1135-1142.
-
(2006)
Clin Gastroenterol Hepatol
, vol.4
, pp. 1135-1142
-
-
Arseneau, K.O.1
Sultan, S.2
Provenzale, D.T.3
-
14
-
-
0000268935
-
Developments in non-expected utility theory: The hunt for a descriptive theory of choice under risk
-
Starmer C. Developments in non-expected utility theory: the hunt for a descriptive theory of choice under risk. J Econ Lit. 2000;38:332-382.
-
(2000)
J Econ Lit
, vol.38
, pp. 332-382
-
-
Starmer, C.1
-
15
-
-
34548490280
-
Crohn's disease patients' riskbenefit preferences: Serious adverse event risks versus treatment efficacy
-
Johnson FR, Ozdemir S, Mansfield C, et al. Crohn's disease patients' riskbenefit preferences: serious adverse event risks versus treatment efficacy. Gastroenterology. 2007;133:769-779.
-
(2007)
Gastroenterology
, vol.133
, pp. 769-779
-
-
Johnson, F.R.1
Ozdemir, S.2
Mansfield, C.3
-
16
-
-
58149191718
-
Are adult patients more tolerant of treatment risks than parents of juvenile patients?
-
Johnson FR, Ozdemir S, Mansfield C, et al. Are adult patients more tolerant of treatment risks than parents of juvenile patients? Risk Anal. 2009;29:121-136.
-
(2009)
Risk Anal
, vol.29
, pp. 121-136
-
-
Johnson, F.R.1
Ozdemir, S.2
Mansfield, C.3
-
17
-
-
65749119370
-
Multiple sclerosis patients' benefit-risk preferences: Serious adverse event risks versus treatment efficacy
-
Johnson FR, Van Houtven G, Ozdemir S, et al. Multiple sclerosis patients' benefit-risk preferences: serious adverse event risks versus treatment efficacy. J Neurol. 2009;256:554-562.
-
(2009)
J Neurol
, vol.256
, pp. 554-562
-
-
Johnson, F.R.1
Van Houtven, G.2
Ozdemir, S.3
-
18
-
-
79959944619
-
Conjoint analysis applications in health - A checklist: A report of the ISPOR Good Research Practices for Conjoint Analysis Task Force
-
Bridges JF, Hauber AB, Marshall D, et al. Conjoint analysis applications in health-a checklist: a report of the ISPOR Good Research Practices for Conjoint Analysis Task Force. Value Health. 2011;14:403-413.
-
(2011)
Value Health
, vol.14
, pp. 403-413
-
-
Bridges, J.F.1
Hauber, A.B.2
Marshall, D.3
-
19
-
-
0031812412
-
A simple clinical colitis activity index
-
Walmsley RS, Ayres RC, Pounder RE, et al. A simple clinical colitis activity index. Gut. 1998;43:29-32.
-
(1998)
Gut
, vol.43
, pp. 29-32
-
-
Walmsley, R.S.1
Ayres, R.C.2
Pounder, R.E.3
-
20
-
-
59849104111
-
Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis
-
Lewis JD, Chuai S, Nessel L, et al. Use of the noninvasive components of the Mayo score to assess clinical response in ulcerative colitis. Inflamm Bowel Dis. 2008;14:1660-1666.
-
(2008)
Inflamm Bowel Dis
, vol.14
, pp. 1660-1666
-
-
Lewis, J.D.1
Chuai, S.2
Nessel, L.3
-
21
-
-
0023521441
-
Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study
-
Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317:1625-1629.
-
(1987)
N Engl J Med
, vol.317
, pp. 1625-1629
-
-
Schroeder, K.W.1
Tremaine, W.J.2
Ilstrup, D.M.3
-
22
-
-
84876390568
-
Crohn's disease and ulcerative colitis are associated with elevated standardized mortality ratios: A metaanalysis
-
Bewtra M, Kaiser L, TenHave T, et al. Crohn's disease and ulcerative colitis are associated with elevated standardized mortality ratios: a metaanalysis. Inflamm Bowel Dis. 2013;19:599-613.
-
(2013)
Inflamm Bowel Dis
, vol.19
, pp. 599-613
-
-
Bewtra, M.1
Kaiser, L.2
Tenhave, T.3
-
23
-
-
0003432464
-
-
American Cancer Society. Accessed April 4, 2011
-
American Cancer Society. American Cancer Society. Available at: http://www.cancer.org/index. Accessed April 4, 2011.
-
American Cancer Society
-
-
-
24
-
-
0035995550
-
Optimal design for Multinomial choice experiments
-
Kanninen BJ. Optimal design for Multinomial choice experiments. J Marketing Res. 2002;39:214-227.
-
(2002)
J Marketing Res
, vol.39
, pp. 214-227
-
-
Kanninen, B.J.1
-
27
-
-
0030506691
-
The importance of utility Balance and Efficient choice designs
-
Huber J, Zwerina K. The importance of utility Balance and Efficient choice designs. J Marketing Res. 1996;33:307-317.
-
(1996)
J Marketing Res
, vol.33
, pp. 307-317
-
-
Huber, J.1
Zwerina, K.2
-
29
-
-
54949085702
-
-
Hoboken, New Jersey: John Wiley & Sons, Inc
-
Dillman DA, Smyth JD, Christian LM. Internet, Mail and Mixed-Mode Surveys: The Tailored Design Method. Hoboken, New Jersey: John Wiley & Sons, Inc.; 2009.
-
(2009)
Internet, Mail and Mixed-Mode Surveys: The Tailored Design Method
-
-
Dillman, D.A.1
Smyth, J.D.2
Christian, L.M.3
-
31
-
-
25144516913
-
Mixed logit with bounded distributions of correlated partworths
-
Alberini A, Scarpa R, eds., Dordrecht, The Netherlands: Springer Publisher
-
Train KE, Sonnier G. Mixed logit with bounded distributions of correlated partworths. In: Alberini A, Scarpa R, eds. Applications of Simulation Methods in Environmental and Resource Economics. Dordrecht, The Netherlands: Springer Publisher; 2005;117-134.
-
(2005)
Applications of Simulation Methods in Environmental and Resource Economics
, pp. 117-134
-
-
Train, K.E.1
Sonnier, G.2
-
33
-
-
79957618829
-
Eliciting benefit-risk preferences and probability-weighted utility using choice-format conjoint analysis
-
Van Houtven G, Johnson FR, Kilambi V, et al. Eliciting benefit-risk preferences and probability-weighted utility using choice-format conjoint analysis. Med Decis Making. 2011;31:469-480.
-
(2011)
Med Decis Making
, vol.31
, pp. 469-480
-
-
Van Houtven, G.1
Johnson, F.R.2
Kilambi, V.3
-
34
-
-
0023324565
-
Perception of risk
-
Slovic P. Perception of risk. Science. 1987;236:280-285.
-
(1987)
Science
, vol.236
, pp. 280-285
-
-
Slovic, P.1
-
35
-
-
0026055338
-
Quality of life of patients with ulcerative colitis preoperatively and postoperatively
-
McLeod RS, Churchill DN, Lock AM, et al. Quality of life of patients with ulcerative colitis preoperatively and postoperatively. Gastroenterology. 1991;101:1307-1313.
-
(1991)
Gastroenterology
, vol.101
, pp. 1307-1313
-
-
McLeod, R.S.1
Churchill, D.N.2
Lock, A.M.3
-
36
-
-
79953780408
-
Perceived and actual quality of life with ulcerative colitis: A comparison of medically and surgically treated patients
-
Waljee AK, Higgins PD, Waljee JF, et al. Perceived and actual quality of life with ulcerative colitis: a comparison of medically and surgically treated patients. Am J Gastroenterol. 2011;106:794-799.
-
(2011)
Am J Gastroenterol
, vol.106
, pp. 794-799
-
-
Waljee, A.K.1
Higgins, P.D.2
Waljee, J.F.3
-
37
-
-
79955866215
-
Individual health discount rate in patients with ulcerative colitis
-
Waljee AK, Morris AM, Waljee JF, et al. Individual health discount rate in patients with ulcerative colitis. Inflamm Bowel Dis. 2011;17: 1328-1332.
-
(2011)
Inflamm Bowel Dis
, vol.17
, pp. 1328-1332
-
-
Waljee, A.K.1
Morris, A.M.2
Waljee, J.F.3
-
38
-
-
84855185627
-
Proximity to disease and perception of utility: Physicians' vs patients' assessment of treatment options for ulcerative colitis
-
Brown LK, Waljee AK, Higgins PD, et al. Proximity to disease and perception of utility: physicians' vs patients' assessment of treatment options for ulcerative colitis. Dis Colon Rectum. 2011;54:1529-1536.
-
(2011)
Dis Colon Rectum
, vol.54
, pp. 1529-1536
-
-
Brown, L.K.1
Waljee, A.K.2
Higgins, P.D.3
-
39
-
-
84857051275
-
Shared decision making in inflammatory bowel disease: Helping patients understand the tradeoffs between treatment options
-
Siegel CA. Shared decision making in inflammatory bowel disease: helping patients understand the tradeoffs between treatment options. Gut. 2012;61:459-465.
-
(2012)
Gut
, vol.61
, pp. 459-465
-
-
Siegel, C.A.1
-
40
-
-
2942530847
-
Mesalamine derivatives in the treatment of Crohn's disease
-
ix-x
-
Harrell LE, Hanauer SB. Mesalamine derivatives in the treatment of Crohn's disease. Gastroenterol Clin North Am. 2004;33:303-317, ix-x.
-
(2004)
Gastroenterol Clin North Am
, vol.33
, pp. 303-317
-
-
Harrell, L.E.1
Hanauer, S.B.2
-
41
-
-
70649110836
-
Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis
-
Sandborn WJ, Regula J, Feagan BG, et al. Delayed-release oral mesalamine 4.8 g/day (800-mg tablet) is effective for patients with moderately active ulcerative colitis. Gastroenterology. 2009;137: 1934-1943.e1-3.
-
(2009)
Gastroenterology
, vol.137
-
-
Sandborn, W.J.1
Regula, J.2
Feagan, B.G.3
|